SEELOS THERAPEUTICS INC's ticker is SEEL and the CUSIP is 81577F109. A total of 29 filers reported holding SEELOS THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $117,183 | +72.9% | 98,061 | 0.0% | 0.07% | +61.9% |
| Q1 2023 | $67,780 | +1.8% | 98,061 | 0.0% | 0.04% | -2.3% |
| Q4 2022 | $66,583 | -35.4% | 98,061 | -1.8% | 0.04% | -41.9% |
| Q3 2022 | $103,000 | +51.5% | 99,819 | 0.0% | 0.07% | +64.4% |
| Q2 2022 | $68,000 | -19.0% | 99,819 | 0.0% | 0.04% | 0.0% |
| Q1 2022 | $84,000 | -52.5% | 99,819 | -7.8% | 0.04% | -48.3% |
| Q4 2021 | $177,000 | -32.2% | 108,286 | 0.0% | 0.09% | -34.1% |
| Q3 2021 | $261,000 | -8.4% | 108,286 | +0.3% | 0.13% | -9.6% |
| Q2 2021 | $285,000 | -73.9% | 107,960 | -50.7% | 0.15% | -53.5% |
| Q1 2021 | $1,092,000 | +360.8% | 218,920 | +45.9% | 0.31% | +129.2% |
| Q4 2020 | $237,000 | +68.1% | 150,000 | 0.0% | 0.14% | +29.2% |
| Q3 2020 | $141,000 | -7.2% | 150,000 | 0.0% | 0.11% | -18.5% |
| Q2 2020 | $152,000 | +105.4% | 150,000 | 0.0% | 0.13% | +46.1% |
| Q1 2020 | $74,000 | – | 150,000 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 2,500,000 | $4,075,000 | 1.71% |
| Connacht Asset Management LP | 498,925 | $813,000 | 0.79% |
| GENDELL JEFFREY L | 2,449,267 | $3,992,000 | 0.32% |
| MANGROVE PARTNERS IM, LLC | 2,133,436 | $3,478,000 | 0.21% |
| Uniplan Investment Counsel, Inc. | 1,550,359 | $2,527,000 | 0.14% |
| Financial Advocates Investment Management | 24,673 | $1,994,000 | 0.13% |
| Connacht Asset Management LP | 72,300 | $118,000 | 0.12% |
| Woodline Partners LP | 4,047,231 | $6,597,000 | 0.09% |
| 1492 Capital Management LLC | 108,286 | $177,000 | 0.09% |
| Ikarian Capital, LLC | 244,171 | $398,000 | 0.06% |